Hyderabad:Dr Reddy's Labshas announced that the Company has received the Establishment Inspection Report (EIR) from the United States Food & Drug Administration (USFDA) for its formulations manufacturing facility FTO 11 in Srikakulam, Andhra Pradesh, India. The USFDA has classified the inspection outcome as 'Voluntary Action Indicated (VAI)' and concluded that the inspection is officially closed under 21 CFR 20.64(d)(3). This follows an inspection conducted by the USFDA in July 2025, during which the company received seven observations. Read also:Dr Reddy's Labs gets 7 USFDA observations for Srikakulam facility Established in 1984, Dr. Reddy’s Laboratories Ltd. is a global pharmaceutical company headquartered in Hyderabad, India. The Company offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr Reddy's Labs major markets include – USA, India, Russia & CIS countries, China, Brazil and Europe. Read also:Dr. Reddy's Labs Gets CDSCO Panel Nod to Manufacture, Market Semaglutide Injection
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
0 Comments
Post a comment
No comments yet. Be the first to comment!